Table 1.

Genes (N = 74) showing increased (n = 42) and decreased (n = 32) expression in invasive breast cancers versus ductal carcinoma in situ (DCIS) in at least 2 groups of samples in this study, and overlap with previous studies comparing human invasive breast cancers and DCIS.

Differentially expressed genesGroups of samples in this study (fold-change)Previous studies (direction significant differences)
SymbolLocus linkGroup 1Group 2Group 3Group 4 epitheliumGroup 4 stromaAverage P-valuePorter 2001Ma 2003Porter 2003Abba 2004Allinen 2004Hanneman 2006Scheutz 2006Ma 2009Knudsen 2011Studies in Common
Increased in invasive breast cancer vs. DCIS
COL1A2a12782.275.233.24.660.00248
MMP11a,b43203.333.194.170.00908
COL11A1c13015.4311.548.955.490.00096
THBS2a70582.057.254.175.670.01376
LRRC15c1315782.685.092.062.430.00556
AEBP1c1652.024.192.350.01376
COL6A3c12933.564.15.550.00866
COL10A1c13002.775.133.340.00956
VCANa14623.592.753.120.01526
POSTNd106313.863.352.990.01866
MXRA5c258783.572.272.640.01016
COL3A1c12813.583.294.870.01906
SPARCd66783.042.220.00765
COL5A2c12902.413.923.650.00866
COL8A1c12952.282.472.160.01546
CILPc84832.0516.094.750.00916
CTSKa,b15133.83.080.02646
FBN1c22004.822.890.01576
HLA-DPA1d31132.022.020.03005
LUMd40604.5730.01605
HLA-DRAc31222.172.070.02944
FN1a23352.892.750.01014
CDH11d10093.82.010.02904
COL5A1c12893.182.260.02984
ASPNd548297.182.70.00264
FAPa21916.614.580.00824
HTRA1d56542.392.140.02334
NID2c227952.052.890.03074
STAT1d67722.112.660.00763
LY96c236433.072.140.01123
COMPd13112.383.110.02543
INHBAd36242.132.590.00923
FCGR3Ac22142.130.00523
FNDC1c846244.543.270.01082
GJB2a27064.164.250.00912
HLA-Gd31352.282.230.00782
CCL5a63522.042.250.02732
CXCL11d63733.524.520.01572
IFI30c104372.213.080.01342
BNC2c547962.222.70.00262
CITED4d1637324.053.30.02072
KANK4c1637823.272.460.01752
Decreased in invasive breast cancer vs. DCIS
MYH11a4629−4.2−3.1−2−2.70.00976
TP63a,b8626−2.5−2.20.02635
DSTc667−5.8−4.6−5.30.02334
SYNMd23336−2.7−2−2.50.02064
C7c730−2.8−3.90.01444
KRT14a3861−2.7−4.30.01874
EFEMP1d2202−2−2.40.00323
DLEU2d8847−2.6−2.20.03713
TINAGL1d64129−2.2−2.40.01333
IL33d90865−2.4−4.80.00923
SERHL2c253190−4.2−3−2.50.00173
DUSP6d1848−2.6−20.00993
INSIG1d3638−2.1−2.50.02803
COL17A1c1308−2.1−2.30.01313
FABP4d2167−2.2−4.50.02433
ENPP2d5168−2.1−2.40.01103
ATP2A2c488−2.1−2.20.01462
CSTAd1475−9.4−3.80.03242
CYP51A1d1595−2.2−2.20.02572
CASP8a841−2.1−2.10.00332
GHRd2690−2.6−2.80.02752
IDH1d3417−2.1−2.30.02612
LEPRd3953−2.1−2.40.04162
MYLKd4638−2.2−2.20.01272
NGFRa4804−2.2−3.70.01272
CAV1a,b857−2.2−2.50.00902
STBD1c8987−2.6−2.10.03282
SLC16A4d9122−2.1−2.90.02282
ATP6V1G1c9550−4.1−2.50.02882
MAFFd23764−2.2−3.20.01972
ADIPOQd9370−3.2−7.00.01752
FAT1a2195−4.9−2.80.00802
Number in 743235214637
Percent in 7443.2%47.3%28.4%62.2%50%
  • aPreviously studied in DCIS, primarily comparing expression levels with invasive breast cancers.

  • bPreviously studied in DCIS, including functional involvement in progression to invasive breast cancer.

  • cNot previously studied in breast cancer.

  • dPreviously studied in invasive breast cancer.